S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
NASDAQ:RCKT

Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis

$24.19
-1.09 (-4.31%)
(As of 04/12/2024 ET)
Today's Range
$23.87
$25.55
50-Day Range
$24.19
$30.74
52-Week Range
$14.89
$32.53
Volume
676,415 shs
Average Volume
640,295 shs
Market Capitalization
$2.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.13

Rocket Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
115.5% Upside
$52.13 Price Target
Short Interest
Bearish
11.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.37mentions of Rocket Pharmaceuticals in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$9.53 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.94) to ($1.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.44 out of 5 stars

Medical Sector

107th out of 927 stocks

Pharmaceutical Preparations Industry

35th out of 435 stocks

RCKT stock logo

About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

RCKT Stock Price History

RCKT Stock News Headlines

SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
See More Headlines
Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
4/14/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RCKT
Employees
268
Year Founded
2018

Price Target and Rating

Average Stock Price Target
$52.13
High Stock Price Target
$65.00
Low Stock Price Target
$39.00
Potential Upside/Downside
+115.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-245,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.46 per share

Miscellaneous

Free Float
62,357,000
Market Cap
$2.19 billion
Optionable
Optionable
Beta
1.07

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Gaurav D. Shah M.D. (Age 49)
    CEO & Director
    Comp: $1.05M
  • Mr. Mayo Pujols (Age 55)
    Chief Technical Officer & Executive VP
    Comp: $649.71k
  • Mr. Raj Prabhakar M.B.A. (Age 50)
    Senior VP & Chief Business Officer
    Comp: $619.13k
  • Kevin Giordano
    Director of Corporate Communications
  • Ms. Isabel Carmona J.D.
    Senior VP & Chief Human Resources Officer
  • Dr. Gayatri R. Rao J.D.
    M.D., Chief Development Officer of LVV & Senior VP
  • Mr. Carlos Martin
    Chief Commercial Officer

RCKT Stock Analysis - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RCKT shares.
View RCKT analyst ratings
or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price target for 2024?

9 equities research analysts have issued 12-month price targets for Rocket Pharmaceuticals' stock. Their RCKT share price targets range from $39.00 to $65.00. On average, they expect the company's share price to reach $52.13 in the next year. This suggests a possible upside of 115.5% from the stock's current price.
View analysts price targets for RCKT
or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2024?

Rocket Pharmaceuticals' stock was trading at $29.97 at the start of the year. Since then, RCKT shares have decreased by 19.3% and is now trading at $24.19.
View the best growth stocks for 2024 here
.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RCKT earnings forecast
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) released its quarterly earnings data on Monday, February, 26th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.14. During the same quarter in the prior year, the business posted ($0.92) EPS.

What ETFs hold Rocket Pharmaceuticals' stock?
What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RCKT) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners